LOC100507599 as molecular marker for diagnosis of laryngeal squamous cell carcinoma

Abstract

The invention discloses an application of LOC100507599 to diagnosis of laryngeal squamous cell carcinoma. The content of LOC100507599 in cancer tissue of patients suffering from laryngeal squamous cell carcinoma has significant differences from that in Precancerous lesions. According to the differences, the patients suffering from laryngeal squamous cell carcinoma and the patients not suffering from the laryngeal squamous cell carcinoma can be distinguished. The invention further discloses a diagnosis product of the laryngeal squamous cell carcinoma, and the diagnosis product can realize the purpose of diagnosis of the laryngeal squamous cell carcinoms by detecting the LOC100507599 in tissue.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to LOC100507599 as a molecular marker for the diagnosis of laryngeal squamous cell carcinoma. Background technique [0002] Laryngeal cancer is a common malignant tumor in the head and neck, accounting for the second place in head and neck tumors, and its incidence rate accounts for about 5% of systemic malignant tumors. Most squamous cell carcinomas originate in the vocal cords, accounting for about 60%. Huang Xinhui et al conducted a retrospective analysis on 306 cases of laryngeal malignant tumors and found that squamous cell carcinoma accounted for 99.7% of all malignant tumors, among which squamous cell carcinoma with high and moderate differentiation was the main type; the primary site of laryngeal cancer was mostly glottic type, Followed by supraglottic type, subglottic type; smoking, drinking are closely related to the occurrence of tumors. Although surgery, radiotherapy, and chemo...

AI Technical Summary

Problems solved by technology

The reasons are mainly manifested in three aspects: First, the early clinical manifestations of laryngeal cancer are diverse, which brings great difficulty to the early diagnosis of laryngeal cancer. Most patients fail to receive timely and effective treatment in the early stage. Molecular markers are the key to improving the early diagnosis rate of laryngeal cancer

Second, the treatment of laryngeal cancer is mainly based on surgery, supplemented by radiotherapy and chemotherapy. Although partial laryngectomy and the early stage of glottic laryngeal cancer are treated with C02 laser treatment, the laryngeal function is completely or partially preserved, and postoperative complications Therefore, the quality of life of patients is improved, but the postoperative recurrence rate is still high. If the tumor-promoting genes or tumor suppressor factors of laryngeal cancer can be found out, and potential drug targets can be screened out, it will be a great opportunity for the development of laryngeal cancer. Cancer-related specific vaccines or / and new anti-cancer drugs lay the foundation

Images